Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Koninklijke Philips N.V. reports health technology developments across Diagnosis & Treatment, Connected Care and Personal Health. News from Royal Philips commonly covers order intake and comparable sales trends; product launches and regulatory clearances for imaging, image-guided therapy and AI software; and governance actions from its Annual General Meeting. Recent product themes include CT platforms such as Rembra and Spectral CT Verida, interventional guidance tools such as DeviceGuide and IntraSight Plus, and the Bridge Plus Occlusion Balloon for lead extraction procedures.
The company’s updates also address hospital monitoring, informatics, ultrasound, oral health and personal-care lines. Coverage reflects Philips’ role as a Netherlands-based global health technology company with securities traded on NYSE under PHG and on Euronext Amsterdam under PHIA.
Royal Philips (NYSE: PHG) and Ibex Medical Analytics have announced a strategic collaboration to promote AI-powered digital pathology solutions globally. This partnership combines Philips' IntelliSite Pathology Solution and Ibex's Galen platform, enhancing diagnostic efficiency with a 27% reduction in reporting time and a 37% productivity increase. The collaboration aims to improve diagnostic accuracy and workflow efficiency in pathology labs, addressing the growing demand for cancer diagnostics. Philips continues to expand its AI-enabled Precision Diagnosis portfolio.
Royal Philips (NYSE: PHG) has received FDA 510(k) clearance for its SmartCT application software, a significant addition to its Azurion Image Guided Therapy System. This software enhances interventionalists' diagnostic confidence and workflow efficiency by providing CT-like 3D imaging directly from a table-side touchscreen within the sterile zone. Key features include advanced 3D image acquisition, visualization, and measurement tools, improving clinical decision-making and patient outcomes. SmartCT is aimed at various procedures, supporting the trend toward minimally-invasive surgery and optimized lab performance.
Royal Philips has partnered with the NHS Cheshire and Merseyside consortium to establish the UK's first regional hub for the National COVID-19 Chest Imaging Database (NCCID). This milestone allows access to 15 years of imaging data from 2.5 million patients, integrating data across 13 NHS trusts. The deployment of a centralized SMART box server enhances data management and facilitates AI technology validation. The NCCID aims to improve understanding of COVID-19 and support AI-driven patient care, emphasizing quick assessments and consistent treatment throughout the healthcare system.
Summary not available.
Philips (NYSE: PHG) and Orbita Inc. have entered a partnership to develop AI-powered virtual assistants for healthcare applications. This collaboration aims to enhance patient engagement and streamline healthcare services. By leveraging Orbita's HIPAA-compliant conversational AI technology, Philips plans to improve digital health solutions across telehealth platforms. The partnership aligns with Philips' strategy to utilize AI for better health outcomes and patient experiences, reflecting the growing demand for efficient healthcare solutions in a rapidly evolving digital landscape.
Summary not available.
On March 25, 2021, Royal Philips (NYSE: PHG) announced the sale of its Domestic Appliances business to Hillhouse Capital for an enterprise value of approximately EUR 3.7 billion. Philips expects to receive around EUR 3 billion in cash proceeds after tax and transaction costs. Additionally, a 15-year brand license agreement will yield an estimated net present value of EUR 0.7 billion, leading to a total deal value of approximately EUR 4.4 billion. This business will be listed as a discontinued operation in Philips' financial statements starting Q1 2021.
Royal Philips (NYSE: PHG) has announced its 2021 Annual General Meeting of Shareholders (AGM) to be held on May 6, 2021. Key agenda items include the reappointment of Mr. Marnix van Ginneken and the appointment of Mrs. Chua Sock Koong and Mrs. Indra Nooyi to the Board. Shareholders can vote and follow the meeting via webcast due to COVID-19 safety measures. The full agenda and the Annual Report 2020 are available on Philips’ website.
Royal Philips, American College of Cardiology (ACC), and MedAxiom have announced a collaboration aimed at improving cardiovascular care. This partnership seeks to enhance clinical outcomes and operational efficiency by integrating guidelines and actionable data across various healthcare stakeholders. Cardiovascular disease, a leading global health challenge, is expected to incur direct medical costs of $749 billion by 2035 in the U.S. The collaboration will utilize Philips' expertise and ACC's extensive resources to address these challenges and improve overall patient care.
Summary not available.